Exo Therapeutics Inc, based in Watertown, MA, is a pioneering biotechnology company that is revolutionizing medicine with its innovative approach to targeting previously untreatable diseases. Through their comprehensive platform, ExoSight, they are expanding the universe of druggable enzymes, unlocking intractable drug targets with precision and potency.
With a focus on oncology and inflammation, Exo Therapeutics is at the forefront of modulating enzyme activity to develop breakthrough medicines. Their lead program, targeting TANK Binding Kinase 1 (TBK1), shows promise in the treatment of autoimmune diseases. Led by a team of experts and recently appointed Executive Chair, Nagesh Mahanthappa, Exo Therapeutics is charting new territory in the quest for innovative therapies.
Generated from the website